Published on
CHOP recipient, physician-scientist Dr. Yael Mossé, is innovating targeted, less toxic therapies for cancer affecting mostly infants and young children.
Published on
Researchers at CHOP are working to discover the fundamental mechanisms that subvert normal neural development and orchestrate neuroblastoma tumorigenesis, and then to translate this knowledge into more effective and less toxic therapies.
Published on
CHOP researchers have identified a powerful new drug with “unparalleled” strength against refractory types of neuroblastoma.
Published on
The history of our understanding and approach to cancer are at the center of CANCER: THE EMPEROR OF ALL MALADIES. The documentary will air in three parts on March 30, 31 and April 1 at 9 p.m. ET on PBS, with the final chapter featuring CHOP.
Published on
The FDA approved Unituxin™ (dinutuximab), which is just the third drug in history to receive initial approval for treatment of pediatric cancer. It is the first immunotherapy drug for children with cancer.